Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/30701
Title: | Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease | Authors: | Capodanno, Davide Bhatt, Deepak L. Eikelboom, John W. Fox, Keith A. A. Geisler, Tobias Gibson, C. Michael Ramon Gonzalez-Juanatey, Jose James, Stefan Lopes, Renato D. Mehran, Roxana Montalescot, Gilles Patel, Manesh Steg, P. Gabriel Storey, Robert F. VRANCKX, Pascal Weitz, Jeffrey I. Welsh, Robert Zeymer, Uwe Angiolillo, Dominick J. |
Issue Date: | 2020 | Publisher: | NATURE PUBLISHING GROUP | Source: | NATURE REVIEWS CARDIOLOGY, 17(4), p. 242-257 | Abstract: | Advances in antiplatelet therapies for patients with cardiovascular disease have improved patient outcomes over time, but the challenge of balancing the risks of ischaemia and bleeding remains substantial. Moreover, many patients with cardiovascular disease have a residual risk of ischaemic events despite receiving antiplatelet therapy. Therefore, novel strategies are needed to prevent clinical events through mechanisms beyond platelet inhibition and with an acceptable associated risk of bleeding. The advent of non-vitamin K antagonist oral anticoagulants, which attenuate fibrin formation by selective inhibition of factor Xa or thrombin, has renewed the interest in dual-pathway inhibition strategies that combine an antiplatelet agent with an anticoagulant drug. In this Review, we highlight the emerging pharmacological rationale and clinical development of dual-pathway inhibition strategies for the prevention of atherothrombotic events in patients with different manifestations of cardiovascular disease, such as coronary artery disease, cerebrovascular disease and peripheral artery disease. Many patients with cardiovascular disease have a residual risk of ischaemic events despite receiving antiplatelet therapy. In this Review, Angiolillo and colleagues discuss the pharmacological rationale and clinical development of dual-pathway inhibition strategies for the prevention of atherothrombotic events in patients with cardiovascular disease. | Notes: | Angiolillo, DJ (reprint author), Univ Florida, Coll Med, Div Cardiol, Jacksonville, FL USA. dominick.angiolillo@jax.ufl.edu |
Other: | Angiolillo, DJ (reprint author), Univ Florida, Coll Med, Div Cardiol, Jacksonville, FL USA. dominick.angiolillo@jax.ufl.edu | Document URI: | http://hdl.handle.net/1942/30701 | ISSN: | 1759-5002 | e-ISSN: | 1759-5010 | DOI: | 10.1038/s41569-019-0314-y | ISI #: | WOS:000507822300001 | Rights: | Springer Nature Limited 2020 | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2021 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
DPI_Nature Revview 2019 (1).pdf | Peer-reviewed author version | 1.22 MB | Adobe PDF | View/Open |
Fig_3.docx | Peer-reviewed author version | 183.76 kB | Microsoft Word | View/Open |
Fig_2.docx | Peer-reviewed author version | 1.52 MB | Microsoft Word | View/Open |
Fig_5.docx | Peer-reviewed author version | 225.02 kB | Microsoft Word | View/Open |
Fig_7.docx | Peer-reviewed author version | 690.72 kB | Microsoft Word | View/Open |
Fig_6.docx | Peer-reviewed author version | 177.46 kB | Microsoft Word | View/Open |
Fig_1.docx | Peer-reviewed author version | 124.42 kB | Microsoft Word | View/Open |
s41569-019-0314-y.pdf Restricted Access | Published version | 2.16 MB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
8
checked on Sep 2, 2020
WEB OF SCIENCETM
Citations
83
checked on Jul 26, 2024
Page view(s)
46
checked on Jul 20, 2022
Download(s)
104
checked on Jul 20, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.